Aprea Therapeutics is accelerating enrollment in its Phase 1 program for APR-1051, a WEE1 kinase inhibitor, after early signals of clinical activity. The company plans to expand active sites from three to 10 and broaden the dose-escalation “backfill” into additional biomarker-defined cohorts, including uterine serous carcinoma and Cyclin E–overexpressing platinum-resistant ovarian cancer. Aprea also adds combination arms in the Phase 1 study, including HPV-positive head and neck squamous cell carcinoma and colorectal cancer, aiming to generate updated data by the fourth quarter and further de-risk the next development stage.